Hims & Hers Health (NYSE:HIMS) Stock Price Up 11.5% Following Analyst Upgrade

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price rose 11.5% on Wednesday after Barclays raised their price target on the stock from $25.00 to $29.00. Barclays currently has an overweight rating on the stock. Hims & Hers Health traded as high as $25.46 and last traded at $26.1660. Approximately 19,819,497 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 32,560,256 shares. The stock had previously closed at $23.47.

A number of other analysts have also issued reports on HIMS. Leerink Partners decreased their price objective on Hims & Hers Health from $20.00 to $17.50 and set a “market perform” rating on the stock in a research note on Tuesday, February 24th. Evercore set a $24.00 target price on Hims & Hers Health in a research note on Tuesday, February 24th. Bank of America raised Hims & Hers Health from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $12.50 to $23.00 in a report on Tuesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, December 29th. Finally, Morgan Stanley lowered their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $30.75.

Insider Activity

In other news, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $308,767.81. Following the completion of the transaction, the insider directly owned 2,126 shares in the company, valued at approximately $78,045.46. This represents a 79.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the transaction, the insider owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 80,463 shares of company stock valued at $2,846,696. 13.71% of the stock is owned by insiders.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Landmark Novo Nordisk partnership — the deal replaces compounded GLP‑1 sales with distribution of branded Wegovy/Ozempic (including new pill forms), materially reducing legal risk and legitimizing HIMS’ platform; analysts and market commentary see this as transformational for revenue and margins. Read More. Read More.
• Positive Sentiment: Analyst upgrades and higher price targets — multiple firms (Barclays, Needham, Deutsche Bank and others) have raised ratings/targets after the Novo news, supporting upside and prompting fresh buy interest. Read More. Read More.
• Positive Sentiment: Large call‑option activity — unusually heavy call buying (322k calls, ~128% above normal) signals speculative and directional bullish positioning that can amplify intraday moves and volatility. Read More.
• Neutral Sentiment: Strong 2025 operating results provide context — HIMS reported $2.35B revenue (+59% YoY), solid EBITDA and cash flow, and 2.5M+ subscribers with improving ARPU/cross‑sell metrics, which support a longer‑term bull case but leave execution risk. Read More.
• Neutral Sentiment: Corporate hire and platform expansion — appointment of a new Chief Communications Officer and product/platform expansions are governance/brand positives but are longer‑dated catalysts. Read More.
• Neutral Sentiment: Mixed brokerage consensus — while a number of firms upgraded, the street average rating remains around “Hold,” so fresh positive headlines may be needed to sustain multiple expansion. Read More.
• Negative Sentiment: Some institutional selling noted — at least one asset manager trimmed/exit positions despite the deal; this could add supply and headwinds if other holders follow. Read More.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. Virtus Advisers LLC bought a new position in shares of Hims & Hers Health during the second quarter valued at about $26,000. Quent Capital LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at about $28,000. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health during the 3rd quarter worth approximately $28,000. Finally, Bogart Wealth LLC increased its stake in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Up 10.3%

The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The stock has a 50 day simple moving average of $24.18 and a 200 day simple moving average of $37.66. The firm has a market capitalization of $5.90 billion, a PE ratio of 50.76, a PEG ratio of 4.55 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business earned $0.11 earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its board has initiated a stock buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.